Vapotherm specializes in high-velocity therapy (HVT), a non-invasive respiratory support technology designed to provide effective treatment for patients experiencing respiratory distress without the need for masks. This innovative approach is particularly beneficial for patients who are mask-intolerant due to various reasons, such as anxiety or physical conditions. The HVT system is versatile, catering to a wide range of patient populations, from neonates in the NICU to adults with chronic obstructive pulmonary disease (COPD). The technology is backed by extensive research, demonstrating its efficacy in preventing intubation and improving patient comfort across different clinical settings.

The HVT 2.0 system, a next-generation device from Vapotherm, enhances the delivery of mask-free respiratory support, allowing healthcare providers to administer treatment with ease and efficiency. The Precision Flow Hi-VNI® feature enables clinicians to deliver high-velocity therapy with a simple push of a button, streamlining the process of care. Vapotherm's solutions are trusted by over 2,400 hospitals worldwide, having treated more than 4.1 million patients, and are recognized for their ability to improve patient outcomes while minimizing the risks associated with traditional mask-based therapies.

United States

Vapotherm, Inc. is the inventor of high flow nasal cannula, and its advanced form: Vapotherm high velocity therapy. Delivering high velocity therapy, the Precision Flow® system offers clinicians a reliable tool for multiple patient populations. For respiratory distress patients presenting in the ED and ICU, high velocity therapy can provide not just oxygenation, but also Mask-Free respiratory support with the comfort of heated humidified high flow. Vapotherm, Inc. is a publicly traded company and its common stock trades on the OTCQX tier of the OTC Markets under the symbol "VAPO".

Vapotherm

Company Details